Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial
To investigate the efficacy and safety of benvitimod compared to halometasone in treating moderate-to-severe chronic hand eczema (CHE), highlighting the need for alternative treatments.
Key Findings:
Benvitimod demonstrated similar efficacy to halometasone in treating moderate-to-severe CHE.
Benvitimod exhibited a more favorable safety profile and tolerability compared to halometasone.
Interpretation:
Benvitimod may serve as an effective alternative to traditional corticosteroid treatments for patients with moderate-to-severe CHE, particularly for those who are refractory to or refuse long-term corticosteroid use.
Limitations:
Single-center study may limit generalizability.
Short follow-up period may not capture long-term efficacy and safety.
Conclusion:
Benvitimod is a promising nonsteroidal treatment option for moderate-to-severe CHE, offering comparable efficacy to halometasone with improved safety.
Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.
